Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study
Jiao Liu,Xiaojun Pan,Sheng Zhang,Ming Li,Ke Ma,Cunyi Fan,Ying Lv,Xiangdong Guan,Yi Yang,Xiaofei Ye,Xingqi Deng,Yunfeng Wang,LunXiu Qin,Zhijie Xia,Zi Ge,Quanhong Zhou,Xian Zhang,Yun Ling,Tangkai Qi,Zhenliang Wen,Sisi Huang,Lidi Zhang,Tao Wang,Yongan Liu,Yanxia Huang,Wenzhe Li,Hangxiang Du,Yizhu Chen,Yan Xu,Qiang Zhao,Ren Zhao,Djillali Annane,Jieming Qu,Dechang Chen
DOI: https://doi.org/10.1016/j.lanwpc.2023.100694
IF: 8.559
2023-01-01
The Lancet Regional Health - Western Pacific
Abstract:BackgroundNirmatrelvir plus ritonavir (Paxlovid) reduced the risk of hospitalization or death by 89% in high-risk, ambulatory adults with COVID-19. We aimed at studying the efficacy and safety of Paxlovid in hospitalized adult patients with SARS-Cov-2 (Omicron BA.2.2 variant) infection and severe comorbidities.MethodsWe conducted an open-label, multicenter, randomized controlled trial in which hospitalized adult patients with severe comorbidities were eligible and assigned in a 1:1 ratio to receive either 300 mg of nirmatrelvir plus 100 mg of ritonavir every 12 h for 5 days with standard treatment or only standard treatment. All-cause mortality on day 28, the duration of SARS-CoV-2 RNA clearance, and safety were evaluated.Findings264 patients (mean age, 70.35 years; 122 [46.21%] female) who met the criteria were enrolled at 5 sites in Shanghai from April 10 to May 19 in 2022. After randomization, a total of 132 patients were assigned to receive Paxlovid treatment plus standard treatment, and 132 patients were assigned to receive only standard treatment. The overall 28-day mortality was 4.92%, 8 patients died in the standard treatment group and 5 died in the Paxlovid plus standard treatment group. There was no significant difference in mortality from any cause at 28 days between the Paxlovid plus standard treatment group and the standard treatment group (absolute risk difference [ARD], 2.27; 95% CI −2.94 to 7.49, P = 0.39). There was no significant difference in the duration of SARS-CoV-2 RNA clearance among the two groups (mean days, 10 in Paxlovid plus standard treatment group and 10.50 in the standard treatment group; ARD, −0.62; 95% CI −2.29 to 1.05, P = 0.42). The incidence of adverse events that occurred during the treatment period was similar in the two groups (any adverse event, 10.61% with Paxlovid plus standard treatment vs. 7.58% with the standard, P = 0.39; serious adverse events, 4.55% vs. 3.788%, P = 0.76).InterpretationPaxlovid showed no significant reduction in the risk of all-cause mortality on day 28 and the duration of SARS–CoV-2 RNA clearance in hospitalized adult COVID-19 patients with severe comorbidities.FundingNational Natural Science Foundation of China (grant number: 82172152, 81873944).